California Public Employees Retirement System boosted its position in AngioDynamics Inc. (NASDAQ:ANGO) by 13.3% during the second quarter, Holdings Channel reports. The institutional investor owned 102,800 shares of the company’s stock after buying an additional 12,100 shares during the period. California Public Employees Retirement System owned 0.28% of AngioDynamics worth $1,477,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the company. Emerald Acquisition Ltd. purchased a new stake in AngioDynamics during the second quarter worth $238,000. KBC Group NV raised its stake in AngioDynamics by 15.2% in the second quarter. KBC Group NV now owns 28,568 shares of the company’s stock worth $411,000 after buying an additional 3,766 shares in the last quarter. California State Teachers Retirement System raised its stake in AngioDynamics by 6.0% in the second quarter. California State Teachers Retirement System now owns 56,586 shares of the company’s stock worth $813,000 after buying an additional 3,183 shares in the last quarter. Bank of New York Mellon Corp raised its stake in AngioDynamics by 2.3% in the second quarter. Bank of New York Mellon Corp now owns 427,529 shares of the company’s stock worth $6,145,000 after buying an additional 9,502 shares in the last quarter. Finally, Strs Ohio raised its stake in AngioDynamics by 76.0% in the second quarter. Strs Ohio now owns 22,700 shares of the company’s stock worth $326,000 after buying an additional 9,800 shares in the last quarter. Institutional investors own 69.29% of the company’s stock.
AngioDynamics Inc. (NASDAQ:ANGO) traded down 1.91% during trading on Tuesday, reaching $16.95. 69,162 shares of the company were exchanged. AngioDynamics Inc. has a 1-year low of $9.71 and a 1-year high of $17.64. The stock’s market capitalization is $622.73 million. The company’s 50-day moving average price is $16.85 and its 200-day moving average price is $14.40.
AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Wednesday, October 5th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. The company had revenue of $88.10 million for the quarter. AngioDynamics had a negative net margin of 11.84% and a positive return on equity of 4.46%. The business’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.11 earnings per share. On average, equities analysts forecast that AngioDynamics Inc. will post $0.66 EPS for the current year.
A number of research firms have recently weighed in on ANGO. Zacks Investment Research upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a report on Wednesday, September 14th. KeyCorp set a $18.00 target price on shares of AngioDynamics and gave the stock a “buy” rating in a report on Monday, September 12th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $15.25.
In other news, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of the business’s stock in a transaction dated Friday, August 5th. The shares were sold at an average price of $14.62, for a total value of $32,763,420.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David F. Burgstahler sold 2,250,000 shares of the business’s stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $14.62, for a total transaction of $32,895,000.00. Following the completion of the sale, the director now owns 23,988 shares in the company, valued at $350,704.56. The disclosure for this sale can be found here. 1.88% of the stock is currently owned by company insiders.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics Inc. (NASDAQ:ANGO).
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.